{"nctId":"NCT03867734","briefTitle":"Aztreonam for Pharyngeal Gonorrhea","startDateStruct":{"date":"2019-04-05","type":"ACTUAL"},"conditions":["Gonorrhea of Pharynx","Gonorrhea"],"count":32,"armGroups":[{"label":"2g Aztreonam","type":"EXPERIMENTAL","interventionNames":["Drug: Aztreonam"]}],"interventions":[{"name":"Aztreonam","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Persons diagnosed with pharyngeal gonorrhea or gonococcal urethritis who are undergoing pharyngeal gonorrhea testing, who are not yet treated.\n\nExclusion Criteria:\n\n* Age less than 16 years\n* Receipt of antibiotics in â‰¤30 days\n* Known allergy to aztreonam\n* History of renal disease (including diagnosis of solitary kidney, chronic renal insufficiency, renal cell carcinoma etc.)\n* Concurrent infection with syphilis or chlamydia\n* Pregnancy and/or nursing\n* Unable to return for a follow-up visit 4-7 days (+/- 1 day).\n* Study team's discretion","healthyVolunteers":true,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Efficacy of Pharyngeal Gonorrhea as Defined as the Proportion of Study Participants With Positive Pharyngeal Gonorrhea Culture at of Enrollment Whose Test of Cure Pharyngeal Culture is Negative","description":"Negative Test of Cure (i.e. Pharyngeal Gonorrhea Culture) after Treatment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of 2 g Aztreonam for N. Gonorrhoeae at Anogenital Sites","description":"Number of individuals with a negative N. gonorrhoeae culture at an anogenital site at test of cure among those who were N. gonorrhoeae culture positive at the respective anatomic site at the enrollment visit.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerability of 2g Aztreonam IM","description":"Subjects' self-report of injection related pain on a scale from 0 - 10 where 0 is no pain and 10 is the worst pain ever.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Side Effects of 2g Aztreonam IM","description":"Subject's report of perceived side effects related to study drug based on responses to standard side effect questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["Headache","Nausea"]}}}